Endologix Inc. Stock Downgraded (ELGX)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Endologix (Nasdaq: ELGX) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Health Care Equipment & Supplies industry. The net income has significantly decreased by 55.5% when compared to the same quarter one year ago, falling from -$5.78 million to -$8.99 million.
  • ENDOLOGIX INC's earnings per share declined by 40.0% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, ENDOLOGIX INC reported poor results of -$0.61 versus -$0.51 in the prior year. This year, the market expects an improvement in earnings (-$0.18 versus -$0.61).
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ENDOLOGIX INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Compared to where it was a year ago, the stock is now trading at a higher level, and has traded in line with the S&P 500. Turning our attention to the future direction of the stock, we do not believe this stock offers ample reward opportunity to compensate for the risks, despite the fact that it rose over the past year.
  • The gross profit margin for ENDOLOGIX INC is currently very high, coming in at 79.52%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -27.02% is in-line with the industry average.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive endovascular repair. Endologix has a market cap of $1.08 billion and is part of the health care sector and health services industry. Shares are up 19.9% year to date as of the close of trading on Friday.

You can view the full Endologix Ratings Report or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains